Prot #A4091056: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Analgesic Efficacy and Safety of a Dose Titration Regimen for the Subcutaneous Administration of Tanezumab in Subjects with Osteoarthritis of the Hip or Knee

Project: Research project

Project Details

Effective start/end date8/2/168/2/19


  • INC Research, LLC (Prot #A4091056 // Prot #A4091056)
  • Pfizer Inc. (Prot #A4091056 // Prot #A4091056)